Tekmira Pharmaceuticals said this week that it has secured a $3 million loan, extending its cash runway into 2013.

Separately this week, Tekmira announced that a trial date of Oct. 30, 2012 has been set for its litigation with Alnylam Pharmaceuticals and AlCana Technologies.

According to the company, Silicon Valley Bank has agreed to provide a $3 million term loan, which can be drawn down at Tekmira's discretion at any time before Sept. 30, 2012. The loan matures on June 30, 2015, and carries a fixed annual interest rate of 8 percent.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.

New Mexico is re-doing its proposed science education standards after criticism, the Associated Press reports.